We are transforming the future of healthcare by predicting those most at genetic risk for developing late-onset Alzheimer’s disease
Cytox’s polygenic risk scoring approaches help pharmaceutical and biotech companies cost-effectively and accurately stratify candidates for clinical trials
Services include genetic risk assessment for amyloid status and cognitive decline, as well as mTOR-associated pathway analysis profiling for more accurate drug targeting
We are transforming the future of healthcare by predicting those most at genetic risk for developing late-onset Alzheimer’s disease
Cytox’s polygenic risk scoring approaches help pharmaceutical and biotech companies cost-effectively and accurately stratify candidates for clinical trials
Services include genetic risk assessment for amyloid status and cognitive decline, as well as mTOR-associated pathway analysis profiling for more accurate drug targeting
LATEST NEWS
Jul 10, 2023
Cytox CEO, Dr. Richard Pither, Talks About genoSCORE™-ACT Genetic Risk Test for Alzheimer's Disease on the UK's Only Dementia-Focussed Radio Show – ‘The 'D' Word With Pete Hill'